Search

Displaying results 3961 - 3970 of 10000 in total
  1. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase … Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors.

  2. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

  3. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations. … [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]

    Categories: Approved Treatments for COVID-19
  4. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

    Categories: Antihistamines for Systemic Use
  5. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long. … In mice and nonhuman primate studies of animals with moderate and severe myelosuppression, in addition to compromised hematopoiesis, oprelvekin was shown to potently induce thrombopoiesis and improve platelet

    Synonyms: IL-11
  6. Pathway

    Joubert Syndrome

    smpdb.ca/view/SMP0000582
    Disease

    Many different gene mutations are responsible for Joubert syndrome, all of the proteins created from these genes affecting the cilia that are found on the cell surface. … The symptoms affect a variety of body parts in the patient, including apnea, ataxia brought on by hypotonia, abnormal eye movements and intellectual disability.

    Drugs: ATP · Calcium · Magnesium cation · Inositol
    Enzymes: Activating molecule in BECN1-regulated autophagy protein 1
  7. Pathway

    Joubert Syndrome

    smpdb.ca/view/SMP0125809
    Disease

    Many different gene mutations are responsible for Joubert syndrome, all of the proteins created from these genes affecting the cilia that are found on the cell surface. … The symptoms affect a variety of body parts in the patient, including apnea, ataxia brought on by hypotonia, abnormal eye movements and intellectual disability.

    Drugs: ATP · Calcium · Magnesium cation · Inositol
    Enzymes: Activating molecule in BECN1-regulated autophagy protein 1
  8. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.

  9. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.

  10. Drug

    Methoxyamine

    go.drugbank.com/drugs/DB06328
    Investigational